Sponsors:
Symposium:
This symposium has one (1) session of invited speakers listed below. Presenters whose topics relate to this symposium are invited to contribute papers to associated session(s) of oral and poster presentations. Program details.
Invited Speakers:
Organizer:
David Smith (Scynexis Corporation)
When and Where:
Both invited and contributed sessions will be held in the Sheraton Imperial Hotel and Convention Center. The invited session is scheduled on Thursday, November 11, 2004. The contributed papers and posters related to this symposium will be coordinated with the invited session. Posters should be sized to fit a 4' x 8' poster board. (Sheraton Floor Plan)
Disclaimer:
This is a working document and changes will be made until the program is finalized.
Abstracts:
Todd L. Graybill: "Flexible Facilities and Synthesis Platforms for Automating Drug Discovery"
The industrialization of modern drug discovery is underway. While individual scientists remain the most valuable and flexible resource available to pharmaceutical R&D, many companies are convinced that drug discovery cycle times can be shortened and drug attrition reduced by appropriately introducing more automation throughout the drug discovery process. Efficient integration of these automated platforms can be a major challenge in the space-confined traditional laboratory environment. Having recognized this fact, GSK has recently commissioned several automation-friendly research facilities worldwide. This presentation will highlight 1) how medicinal chemists are exploiting these large, flexible laboratories and 2) some advantages and limitations of several automated synthesis platforms in use. A modular solid-phase synthesis platform that employs ceramic 2D bar-coded reaction vessels and automated workstations for sorting and cleavage will be highlighted.
Gary Kramer "Analytical Information Markup Language (AnIML) for Spectroscopy and Chromatography Data"
The Analytical Information Markup Language (ANIML) is being developed by ASTM subcommittee E13.15 on Analytical Data Management as a "web-aware" mechanism for instrument-to-instrument, instrument-to-application, and application-to-application data interchange and archiving. AnIML is based in part on NIST's SpectroML markup language for uv-vis spectroscopy data and ThermoElectron's Generalized Analytical Markup Language (GAML) and borrows heavily from older interchange standards such as IUPACıs JCAMP-DX and ASTMıs ANDI, from existing data dictionaries, and from other relevant markup language efforts. AnIML is comprised of two major parts. The AnIML Core, whose structure is described by an XML (Extensible Markup Language) schema, provides means to organize and represent arbitrary analytical data. AnIML Technique Layers formally define the structure of data and metadata for specific analytical techniques and take the form of XML instance documents. A Technique Schema provides the meta-representation for the Technique Layers, which are extensible to permit vendor, enterprise, and/or user extensions to the data representation. Utilizing extension data will require custom software; however, its presence in an AnIML file should not break generic software applications. A software tool(the AnIML Validator) has been created to check such instance documents for completeness, for proper syntax, and, in a limited way, for semantic content. Another software tool (the AnIML Technique Creator) allows analytical domain experts lacking XML expertise to create Technique Layer instance documents. Adherence to the AnIML standard permits the creation of generic data viewers that can function inside XML-aware programs, such as Microsoft's Internet Explorer (versions > 6.0). With such a viewer, a user should be able to look at result data from any analytical technique in AnIML format. However, manipulating such data will require an advanced viewer or custom software.
Albert Van den berg: "Potential of Micro- and Nanofluidics for Labs-on-a-Chip and Labs-in-a-Cell"
The realization of Lab-on-a-Chip systems is for a large part based upon microfabrication techniques enabling microfluidic structures. The control of fluid flows in channels several tens of microns wide combined with miniaturized separation and detector integration has enabled construction of microsystems such as microneedle arrays, miniaturized systems for ppb ammonia detection, chips for lithium analysis in (whole) blood, miniaturized NMR chips and chips for hydrodynamic separations (HDC chips). In particular the lithium chips are currently being used to study the monitoring of patients using lithium medication in collaboration with the MST hospital in Enschede. Recently, a further downscaling to the area of nanofluidics (typical dimension <100 nm) has opened the way to develop tools to use a single cell as experimentation platform, a so-called Lab-in-a-Cell (LIC). Several devices for use in such LIC systems, such as nanochannels, nanopipettes and (sub)micron pores will be presented, and potential realizations of this concept enabling cell-experimentation on-chip will be discussed. So far, we have been able to obtain single-cell mass spectra. Future possibilities to use chip formats to evaluate drugs supplied on the single cell level will be discussed. [Figures will be included in the full abstract.]
Paul Watts: "Miniaturisation of Chemical synthesis to Improve the Efficiency of Drug Discovery"
Drug discovery is a very time consuming process, with one of the slowest steps being the synthesis and purification of potential candidates. Several companies have acknowledged that the miniaturisation of chemical reactors offer many fundamental and practical advantages of relevance to the pharmaceutical industry, who are constantly searching for automated, high throughput methods for the synthesis and purification of products with a high degree of chemical selectivity. In this presentation a number of chemical reactions of pharmaceutical interest will be used to illustrate the advantages that micro reactors offer for the rapid optimisation of reactions, in which the product is typically produced in both higher yield and purity. It will be illustrated that compounds may be prepared and purified within an integrated system, in sufficient quantities for biological evaluation to be performed. Furthermore, it will be demonstrated that it is possible to generate intermediates in situ within the reactor, which may then be subsequently reacted to produce more complex products. It will also be shown that integration of the micro reactor to a highly sensitive microchannel-based biological assay system would enable rapid screening to be performed.
Updated: September 1, 2004
Page maintained by:
bill_switzer@ncsu.edu